Future prospects in prostate cancer

Prostate

Volumn 40, Issue 4, 1999, Pages 261-268

  Hegarty, Nicholas J ^a   Fitzpatrick, John M ^a   Richie, Jerome P ^b   Scardino, Peter T ^c   DeVere White, Ralph W ^d   Schröder, Fritz H ^e   Coffey, Donald S ^f  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Gene therapy; Nomograms; Prostate cancer; Tumor biology

Indexed keywords

ACYLTRANSFERASE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CADHERIN; CASPASE; CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; ENDOSTATIN; GLUTATHIONE TRANSFERASE; GONADORELIN DERIVATIVE; GROWTH FACTOR; HORMONE; INTEGRIN; IODINE 125; IRIDIUM 192; MATRIX METALLOPROTEINASE; MEMBRANE ANTIGEN; OLIGONUCLEOTIDE; PALLADIUM; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; TELOMERASE; THALIDOMIDE; THYMIDYLATE SYNTHASE INHIBITOR; TUMOR MARKER; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CONTROL; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; GENE THERAPY; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

CLINICAL TRIALS; DISEASE PROGRESSION; GENE THERAPY; HORMONES; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032791832     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H     Document Type: Article

References (82)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-30.
2. Partin AW, Briggman JV, Subong ENP, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear proteins. Urology 1997;50:800-808.
3. Qian J, Bostwick DG, Takahashi S, Borrell TJ, Brown JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996;149:1193-1199.
4. Emmert Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996;274:998-1001.
5. Malins DC, Polissar NL, Gunselman SJ. Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH) and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Proc Natl Acad Sci USA 1997;94:259-264.
6. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JL, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localised prostate cancer. J Urol 1993;149:1478-1481.
7. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
8. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
9. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48: 47-57.
10. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostate carcinoma. The role of neovascularity. Cancer 1994;73:869-875.
11. Catalona WJ. Surgical management of prostate cancer: contemporary results with anatomic radical prostatectomy. Cancer 1995;75:1903-1908.
12. Gohagan JK, Prorak PC, Kramer BS, Cornett JE. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute. J Urol 1994;152: 1905-1909.
13. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994;152:1910-1914.
14. Schröder FH, Denis L, Kirkels W, de Konig HJ, Standaert B. European Randomized Study of Screening for Prostate Cancer. Cancer 1995;76:129-134.
15. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993;270:948-954.
16. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997; 157:2212-2218.
17. Newcomber LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997;158:1427-1430.
18. Beck JR, Kattan MK, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1992;152:1894-1899.
19. Cole P, Rodu B. Declining cancer mortality in the United States. Cancer 1996;78:2045-2048.
20. Lu-Yao GI, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-910.
21. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systemic biopsies. J Urol 1996;156:1059-1063.
22. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with T1C adenocarcinoma of the prostate. J Urol 1997;157:2206-2209.
23. Chevalier S, Aprikian AG, Beauregard G, Defoy I, Nguyen LT, Guenette RS, Tenniswood M, Chapdelaine A. Action, localization and structure-function relationship of growth factors and their receptors in the prostate. Reprod Med Rev 1996;5:73-105.
24. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
25. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-167.
26. Fudge K, Bosrwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-286.
27. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta with prostate cancer: an immunohistochemical study. Hum Pathol 1993;24:4-9.
28. Sommerfield HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-222.
29. Steiner M, Barrack ER. Transforming growth factor-β overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
30. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995;73:628-635.
31. Lee C. Cellular interactions in prostate cancer. Br J Urol [Suppl] 1997;79:21-27.
32. Umbas R, Isaacs WB, Bringeur PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken J. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
33. Umbas R, Isaacs WB, Bringeur PP, Xue Y, Debruyne FMJ, Schalken J. Relation between aberrant α-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997; 74:3;74-377.
34. Thompson IM, Coltman CA Jr, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 1997;33:217-221.
35. Roth J, Mukhopadhyay T, Zhang WW, Fujiwara T, Georges R. Gene replacement strategies for the prevention and therapy of cancer. Eur J Cancer 1994;30:2032-2037.
36. Donovan JF, Lubaroff DM, Williams RD. Immunotherapy of prostate cancer. Probl Urol 1990;4:489-505.
37. Sikora K, Pandha H. Gene therapy for prostate cancer. Br J Urol [Suppl] 1996;79:64-68.
38. Harris J, Guttierez A, Hurst H, Sikora K, Lemoine N. Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther 1994;1:174-179.
39. Anderson WF. Human gene therapy [review]. Nature [Suppl] 1998;392:25-30.
40. Scardino PT, Adler HL, Herman JR, Woo SLC, Aguilar-Cordova E, Timme TL, Thompson TC. Herpes simplex virus-thymidine kinase (HSV-tk) mediated gene therapy is safe and active against locally recurrent prostate cancer after irradiation therapy [abstract]. Proc ASCO 1998;17:308.
41. Brendler CB, Walsh PC. The role of radical prostatectomy in the treatment of prostate cancer. CA Cancer J Clin 1992;42:212-222.
42. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immunotherapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15.
43. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996;23:587-604.
44. Paulson DF, Moul JW, Robertson JE, Walther PJ. Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990;143: 1178-1182.
45. Freeman JA, Lieskovsky G, Cook DW, Petrovich Z, Chen SC, Groshen S, Skinner DG. Radical retropubic prostatectomy and postoperative adjuvant radiation for pathologic stage C (PcNO) prostate cancer from 1976 to 1989. J Urol 1993;149:1029-1034.
46. Schellhammer P, Cockett A, Boccon Gibod L, Gospodarowicz M, Krongrad A, Thompson IM, Scardino PT, Soloway M, Adolfsson J. Assessment of endpoints for clinical trials for localized prostate cancer. Urology [Suppl] 1997;49:27-38.
47. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology 1997;11:1133-1140.
48. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
49. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localised (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
50. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RE, Storme G, Bernier J, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer with radiotherapy and goserelin. N Engl J Med 1997;337: 295-300.
51. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
52. Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993;42:119-130.
53. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269.
54. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, Dorr FA, Benson M, Spaulding JT. Prognostic factors in stage D2 prostate cancer: important implications for future trials: results of a Cooperative Intergroup study (INT .0036). Semin Oncol 1994;21:613-619.
55. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
56. Iverson P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting Smith K, Blackledge GR. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-396.
57. Schuurmans AL, Bolt J, Veldscholte J, Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate tumour cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 1990;37:849-853.
58. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607-609.
59. Herrada J, Dierenger P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996;155:620-623.
60. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-844.
61. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998;51:137-144.
62. Higano CS, Ellis W, Russell W, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48:800-804.
63. Walsh PC. Urological survey. J Urol 1998;160:270-271.
64. Dhom G. Epidemiologic aspects of latent and clinically manifest carcinoma. J Cancer Res Clin Oncol 1983;106:210-218.
65. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-746.
66. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases in Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
67. Morton MS, Matos Ferreira A, Abranches Monteiro L, Correia R, Blacklock N, Chan PS, Cheng C, Lloyd S, Chieh Ping W, Griffiths K. Measurement and metabolism of isoflavonoids and lignans in the human male. Cancer Lett 1997;114:1-2.
68. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997;29:95-120.
69. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990;10:1307-1312.
70. Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, Mettlin C, Pontes JE. Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 1983;70:687-692.
71. Veierod MB, Laake P, Thelle DS. Dietary fat and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997;73:634-638.
72. Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two year prostate specific antigen and biopsy results. Urology 1996;47:395-401.
73. Miller RJ, Cohen JK, Shuman BA, Merlotti L. Percutaneous transperineal cryoablation of the prostate as salvage therapy for post-radiation recurrence of adenocarcinoma. Cancer 1996;77/ 78:1510-1514.
74. Zlotta AR, Djavan B, Matos C, Noel JC, Peny MO, Silverman DE, Marberger M, Schulman CC. Percutaneous transperineal radiofrequency ablation of prostate tumor: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998;81:265-275.
75. Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavaanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996; 23:633-650.
76. Butler EB, Scardino PT, Teh BS, Uhl M, Guerriero WG, Carlton CE, Berner BM, Dennis WS, Carpenter LS, Lu HH, Chiu JK, Kent TS, Woo SY. The Baylor College of Medicine experience with gold seed implantation. Semin Surg Oncol 1997;13:406-418.
77. Whitmore WH, Hilaris B, Sogani P, Herr H, Batata M, Fair W. Interstitial irradiation using I-125 seeds. Prog Clin Biol Res 1987; 243:177-195.
78. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
79. Tjoa B, Murphy GP. Hope of a new prostate cancer vaccine. Prostate Cancer Prostate Dis 1997;1:45-46.
80. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997;94:10868-10872.
81. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
82. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294.